Keyword: Merck & Co.

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.

Merck has put up some monster Keytruda-chemo combo numbers that'll raise the bar for rivals looking to steal the class crown.

With both Merck and Bristol-Myers Squibb rolling out closely watched data this weekend, one analyst has already tapped Merck as the early winner.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.

Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.

Here is some other vaccine news of note for the week.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.

Top drugmakers benefited from tax reform, but a new report says several companies passed that benefit on to shareholders and executives, not to patients.